TargetMol

Dacarbazine hydrochloride

Product Code:
 
TAR-T1120L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1120L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1120L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1120L-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Dacarbazine ( imidazole carboxamide) is a chemotherapy drug used to treat melanoma and Hodgkin's lymphoma.
CAS:
17925-90-5
Formula:
C6H11ClN6O
Molecular Weight:
218.65
Purity:
0.98
SMILES:
Cl.CN(C)N=Nc1[nH]cnc1C(N)=O

References

1. Xiao Y, Liu J, Liu YC, Huang XE, Guo JX, Wei W. Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Asian Pac J Cancer Prev. 2014;15(9):3951-4. PubMed PMID: 24935579. 2. Maafi M, Lee LY. Determination of Dacarbazine ?-Order Photokinetics, Quantum Yields, and Potential for Actinometry. J Pharm Sci. 2015 Oct;104(10):3501-9. doi: 10.1002/jps.24568. Epub 2015 Jul 14. PubMed PMID: 26173629. 3. Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration. Int J Pharm Compd. 2006 May-Jun;10(3):234-6. PubMed PMID: 23974237. 4. Nitta Y, Ikeya T, Sakakibara A, Tomita Y. Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma. J Dermatol. 2011 Feb;38(2):164-8. doi: 10.1111/j.1346-8138.2010.00947.x. Epub 2010 Nov 11. PubMed PMID: 21269313.